HRT Prioritizes Access To Affordable Naloxone As US FDA Approves Second OTC Formulation

 
• By Malcolm Spicer
RiVive nasal spray is second OTC naloxone formulation approved in US. • Source: Harm Reduction Therapeutics

More from Rx-to-OTC Switch

More from Health